Shane Olwill appointed as chief development officer at Asgard Therapeutics
Ella Day | March 28, 2025 | Appointment | Business Services, Clinical Research | Asgard Therapeutics, CDO, Oncology, appointment, immunology
Asgard Therapeutics has announced the appointment of Shane Olwill as chief development officer (CDO). The biotech company develops in vivo direct cell reprogramming for cancer immunology.
Olwill specialises in immunology drug development. In his new position, he will lead Investigational New Drug (IND)-enabling studies and clinical trials planning for Asgard’s AT-108 therapy. This is a cell-programming therapy that focuses tumour cells to present their own tumour antigens, prompting a personalised immune response tailored to target each patient’s cancer.
Olwill previously worked at Pieris Pharmaceuticals, now merged with NASDAQ-listed Palvella Therapeutics, where he developed clinical programmes in immuno-oncology and respiratory diseases. Prior to this he was director of research at Fusion Antibodies.
The new CDO commented: “Asgard’s in vivo cell reprogramming technology, based on the deep research and understanding of its founders, is a potentially transformative new form of cancer immunotherapy that is not only powerful but also indication-agnostic. I’m delighted to be joining the company”.
Cristiana Pires, co-founder and chief executive officer of Asgard Therapeutics, said: “Shane’s skill set, derived from his extensive experience of pipeline development, particularly in immuno-oncology, is highly complementary to the other members of our team and will be of great benefit as we move forwards.”
Ella Day
28/3/25
Related Content
Chronic spontaneous urticaria – the impact on patient quality of life, ongoing developments in treatments and the importance of greater awareness
The current forms of immunotherapy, how T cell therapy works and what the future holds
A challenge we can no longer ignore: meeting the needs of people with Crohn’s Disease in the UK
By Holly Thomas, Associate Vice-President Specialty Care at Lilly UK and Ireland Immunology care in …
FDA grants orphan drug designation to antibody-mediated rejection treatment
Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug …
